India, Oct. 27 -- Shares of several biotech companies moved higher following quarterly financial results, clinical pipeline updates and strategic developments. Kiniksa Pharmaceuticals raised its 2026 ARCALYST revenue outlook, Pluri announced a U.S. commercialization partnership with ZEO ScientifiX, Wave Life Sciences advanced its RNA medicine programs, and Zura Bio outlined upcoming clinical milestones.
Read on.....
Zura Bio Limited (ZURA)
Shares of Zura Bio surged 21% after the company reported third-quarter 2026 results and provided updates on its clinical pipeline. Net loss increased to $25.8 million, or $0.20 per share, from $20.0 million, or $0.21 per share, in the prior-year quarter. Research and development expenses rose to $19.5 ...